Maxpro Capital Acquisition, a blank check company formed by Taiwan's Maxpro Ventures targeting healthcare and tech, raised $90 million by offering 9.0 million units at $10. Each unit consists of one share of common stock and one warrant, exercisable at $11.50.
The company is led by CEO and Chairman Moses Chen, who currently serves as Managing Director of Maxpro Ventures and previously served as Acting COO of SyneuRx International.
Maxpro Capital Acquisition plans to target the healthcare and technology sectors, as well as technologically advanced segments of the medical, biotechnology, digital, data and data science, industrial, and financial fields. It plans to focus on businesses with enterprise values between $200 million and $2 billion, initially prioritizing those in North America, Europe, and Asia.
Maxpro Capital Acquisition plans to list on the Nasdaq under the symbol JMACU. EF Hutton acted as sole bookrunner on the deal.
